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Abstract
Background: Clear cell sarcoma of tendons and aponeuroses (CCSTA) appears usually in the
extremities and rarely in the trunk.
Case presentation: We present an unusual case of CCSTA overlying the scapular region and
with secondary osseous extension in the lower scapula. The patient underwent a wide local
excision with removal of the tumor and the lower two thirds of the scapula. He had no local
recurrences but he developed lung metastases after 5 months in spite of postoperative
chemotherapy. He finally died ten months later.
Conclusion: The patients with CCSTA have a variable unpredictable course. Despite treatment
the overall prognosis is poor.
Background
Clear cell sarcoma of tendons and aponeuroses (CCSTA),
first described by Enzinger in 1965[1], is a rare tumor
accounting for less than 1% of all soft tissue sarcomas [2].
It has a clear distinction from metastatic melanoma.
Patients with CCSTA have a variable unpredictable prog-
nosis. This tumor has a predilection for the lower and
upper limbs and rarely presents in the trunk. Sporadic
cases only have been reported of CCSTA involving prima-
rily the bone or extending from soft tissues to surrounding
bones. We report an unusual case of CCSTA in the left
lower scapular region with secondary osseous invasion of
the scapula.
Case presentation
A 61-year-old man presented with a painful mass overly-
ing the lower left scapula of four months duration. His
pain deteriorated the last three weeks and was accompa-
nied by limitation of the range of motion of the left gleno-
humeral joint.
Physical examination revealed a subcutaneous tender uni-
formly firm mass in the lower left scapular region measur-
ing 4.5 × 4.5 cm in diameter. There were no signs of
superficial skin inflammation. The patient had not a pre-
vious history of melanoma and/or other skin tumors.
Radiological examination showed an osteolytic lesion in
the lower left scapula while bone scanning was positive
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with increased uptake in the same area. CT scans and MRI
images of the thorax and shoulder showed a soft tissue
mass 45 × 45 mm localized in the lower scapular region
between infraspinatus and teres minor muscles with bone
invasion of the lower part of the scapula (Figure 1, 2, 3).
There were no lung metastases neither axillary nor medi-
astinal lymph nodes.
The open biopsy specimen consisted of a rubbery,
homogenous, white tissue with no attachment to the skin,
implying deep location of the tumor. There were compact
nests and fascicles with large rounded and spindle-shaped
cells separated by connective tissue septa. The large
rounded cells had pleomorphic nuclei and large amounts
of clear cytoplasm while the spindle-shaped cells had
palely staining eosinophilic cytoplasm. Mitoses were
moderately numerous. There were areas of necrosis and
hemorrhage and tumor spreading into the surrounding
muscles and scapula. Immunohistochemical stains were
performed with negative staining for CD68, actin and
desmin antigens and with positive staining for tumor
markers S-100 protein, HMB-45, NSE, EMA, cytokeratins
and myosin. Histochemical stains for melanin presence
were negative. Pathologic findings were compatible with
a CCSTA with osseous extension into the lower scapula
(Figure 4, 5).
After three days a wide excision was carried out and the
tumor was removed together with the two thirds of the left
scapula and the overlying soft tissues. The remaining bone
and soft tissue margins were widely free of tumor. Macro-
scopic and pathologic examination of the removed mass
confirmed the primary diagnosis.
Postoperatively the patient started on a chemotherapy
protocol (three courses) consisting of ifosfamide, vincris-
tine and epirubicin. The patient had no local recurrences
but he developed lung metastases after 5 months. Despite
Saggital MRI image through the scapular region showed the  soft tissue tumor Figure 3
Saggital MRI image through the scapular region showed the 
soft tissue tumor.
Axial CT scan revealed a soft tissue mass localized in the  lower scapular region with intralesional calcifications and a  secondary osseous invasion of the lower scapula Figure 1
Axial CT scan revealed a soft tissue mass localized in the 
lower scapular region with intralesional calcifications and a 
secondary osseous invasion of the lower scapula.
MRI image established the tumor measuring 45 × 45 mm Figure 2
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chemotherapy, he died 10 months later with progressive
lung disease.
Discussion
CCSTA is an aggressive rare soft-tissue tumor with approx-
imately 300 cases totally reported in the English literature
[3]. It's a slowly growing tumor often with a long period
from the first symptom to diagnosis (averaged 2 years)
and seems to have no specific sex predilection. CCSTA can
occur in patients of any age. The median age of the
patients at the time of diagnosis is 29 years old [4]. In our
case the interval between the presentation and the treat-
ment was 4 months suggesting a fast growing tumor.
Commonly the presenting symptom is a painless mass or
swelling. Pain and/or tenderness above the tumor site
may be found in 33–50% of all the patients suffered from
CCSTA. Typically CCSTA has the appearance of a palpable
deep-located soft tissue mass bound to an adjacent ten-
don or aponeurosis. The overlying skin may occasionally
appear with discoloration [4,5]. Intralesional calcifica-
tions are rarely seen and primary [2,6,7] or secondary
[8,9] bone invasion by this tumor is very rare.
Frequently it arises in the extremities with a predilection
for the lower limbs (78–97%). Both foot and ankle are the
commonest sites of tumor appearance accounting 33–
65% of all cases. Next most common sites are the knee,
thigh, hand, forearm, elbow and shoulder in descending
order of frequency; rarely the tumor arises in the head,
neck or trunk [5,10,11].
Primary CCSTA overlying the scapular region, as in our
case, is very uncommon with only a few case reports have
been described [5,12]. This tumor has an unclear histolog-
ical origin; there are many theories concerning histogene-
sis of CCSTA such as synovial origin, neural crest
derivation or being an atypical malignant melanoma
[5,12]. Tsuneyoshi et al [12] subdivided CCSTA into syn-
ovial and melanotic types based of melanin presence and
histological and cytological differences.
Usually CCSTA has the appearance of a lobular or multi-
nodular, circumscribed or encapsulated mass with a gray-
white appearance on cut surface. Hemorrhage and necro-
sis may be present in large tumors. Intralesional calcifica-
tions are rarely seen [13]. Histologically, CCSTA is
composed of round and/or fusiform cells arranged in
nests separated by fibrocollagenous tissue. These cells
have a relatively uniform appearance of round to ovoid
vesicular nuclei with prominent nucleoli and with clear
(in two-thirds of tumors perhaps due to intracytoplasmic
glycogen) or eosinophilic cytoplasm. A small number of
giant cells with more than 12–15 nuclei may be seen [14]
but there were not wreath-like giant cells in our case.
Fibrous tissue septa are often contiguous with the fibers of
the involved tendons and aponeuroses.
Immunohistochemically, the tumor cells are usually pos-
itive for S-100 protein, HMB-45 and vimentin and/or
microphthalmia transcription factor [14]. Cytokeratins
(low molecular weight) may be found in the tumor cells
[15]. Usually intracellular melanin is scanty[14] although
many reported series refer that about 50–75% of CCSTA
Immunohistochemical staining for S-100 showing cytoplasmic  positivity Figure 5
Immunohistochemical staining for S-100 showing cytoplasmic 
positivity. Magnification ×200.
Clear cell sarcoma tissue section: compact nests and fascicles  with large rounded and spindle-shaped cells separated by  connective tissue septa Figure 4
Clear cell sarcoma tissue section: compact nests and fascicles 
with large rounded and spindle-shaped cells separated by 
connective tissue septa. Mitoses are numerous. The cells had 
large amounts of clear cytoplasm (H&E ×200).World Journal of Surgical Oncology 2006, 4:48 http://www.wjso.com/content/4/1/48
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contain variable amounts of melanin which can be iden-
tified by melanin stains [4,5,11,12]. Ultrastructurally
melanosomes may be present [14]. In our case the tumor
did not contain melanin.
CCSTA is associated with chromosomal abnormalities
consisting of changes in chromosome number and chro-
mosome rearrangements [9,14,16]. Cytogenetic analysis
of CCSTA identifies abnormalities in most chromosomes.
A t(12;22)(q13;q12) translocation may be found in 75%
of cases with CCSTA by karyotype analysis. Many authors
suggest that this translocation seems to be pathogno-
monic for CCSTA [9,17].
Distinction between CCSTA and metastatic malignant
melanoma may have diagnostic difficulties. Both tumors
have similar histological features. However tumor presen-
tation (especially location, cutaneous involvement, pri-
mary melanoma elsewhere) and histological features help
to make a differential diagnosis between these tumors
[14]. Both CCSTA and malignant melanoma are immuno-
histochemically positive for S-100 protein (a marker for
tumors derived from neural crest) and HMB-45 (a marker
identifying tumors associated with melanoma) [18] sug-
gesting that these tumors have a close relationship. Pri-
mary and metastatic melanoma usually has a different
genetic profile. The t(12;22)(q13;12) translocation has
not yet been identified in melanoma [9,14]. Recent
reports refer that there is a high incidence of activating
mutations in the kinase domain of the BRAF gene in
malignant melanoma of the skin while in CCSTA the
BRAF mutations are rare [19,20].
The treatment of choice for patients with CCSTA is wide
excision of the tumor or amputation with excision of
regional lymph nodes. Adjuvant radiotherapy and/or
aggressive multiagent chemotherapy seem to be ineffec-
tive but probably could be given [3-5,21,22]. Surgical
excision, adjuvant radio- or chemotherapy or a combina-
tion of these three treatments seems to have no advantage
of one therapy over another [4,21]. Our patient was sub-
mitted to surgical excision and chemotherapy and yet
died after only ten months.
The patients with CCSTA have a variable unpredictable
course. Despite treatment the overall prognosis is poor
and subsequent wide spread dissemination of disease lead
patients with CCSTA to death. The 5-year survival rate
with radical excision and adjuvant chemotherapy and/or
radiotherapy ranged from 60 to 67% and the 10-year sur-
vival rate is about 33% [4,5,10,11]. The incidence of local
recurrence after primary surgical treatment is very high.
Enzinger [1] reports incidence of 84% of first local recur-
rence (with 1–10 subsequent local recurrences), while in
the series reported by Pavlidis [5] 5 of six cases developed
local recurrence in 3 to 9 months.
Usually there is a median interval time between the pri-
mary treatment and first local recurrence ranged from 6
months to 1 year [11,12]. Therefore primary wide surgical
excision of the tumor is warranted to decrease local recur-
rences. In our case no local recurrence was present after
ten months.
The most common sites of metastases are the regional
lymph nodes and the lungs and less common skin, bones,
liver, heart and brain [2,5,11]. 60–70% of patients with
CCSTA develop metastases at a mean time interval of 18
months to 6 years [1,5]. Perhaps preoperative duration of
symptoms, tumor size, mitotic index or vascular invasion
may not predict survival in these patients [5]. Some
authors believe that the size of tumor defines a better or
worse survival. Tumors greater than 5 cm have a worse
survival and they warrant more aggressive local surgical
treatment being at high risk of distant metastases [3,21]
while in Deenik series [22] patients with tumor size less
than 2 cm had a better survival.
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